Trial reportCells2020
Migration Inhibitory Factor in Conditioned Medium from Human Umbilical Cord Blood-Derived Mesenchymal Stromal Cells Stimulates Hair Growth.
Trial report in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- A systematic review of clinical evidence on the efficacy and safety of conditioned media, platelet-rich fibrin, stromal vascular fraction, extracellular vesicles, and stem cells in androgenetic alopecia.Stem cell research & therapy · 2026Pooled it
- Stem cell therapy alleviates hair loss caused by COVID-19 vaccination.Journal of exercise rehabilitation · 2026Article
- Oxidative stress activates the transplanted adipose-derived stem cells to exert antioxidant effects in alopecia treatment.Redox report : communications in free radical research · 2025Article
- Macrophage migration inhibitory factor: Exploring physiological roles and comparing health benefits against oncogenic and autoimmune risks (Review).International journal of molecular medicine · 2025Review
- Lithium chloride-treated human umbilical cord mesenchymal stem cells-derived exsomes promote hair growth by regulating miR-146a-5p-wnt pathway.Stem cells translational medicine · 2025Article
- A molecular systems architecture of the mesenchymal stromal cell microenvironment.Stem cells (Dayton, Ohio) · 2025Article
- The potential ofRegenerative therapy · 2025Article
- Review
- Transcriptome sequencing reveals the key genes associated with hair follicle development in Qianhua Mutton Merino.Frontiers in veterinary science · 2025Article
- Safety assessment of multiple systemic administration of human mesenchymal stem cell-conditioned medium for various chronic diseases.PloS one · 2025Article
- Materials-based hair follicle engineering: Basic components and recent advances.Materials today. Bio · 2024Review
- Minoxidil Nanosuspension-Loaded Dissolved Microneedles for Hair Regrowth.AAPS PharmSciTech · 2024Article
- Autologous Stem Cell-derived Therapies for Androgenetic Alopecia: A Systematic Review of Randomized Control Trials on Efficacy, Safety, and Outcomes.Plastic and reconstructive surgery. Global open · 2024Article
- Effects of microenvironment and biological behavior on the paracrine function of stem cells.Genes & diseases · 2024Review
- Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review.Skin appendage disorders · 2023Article
- The Effect of Mesenchymal Stem Cells Derived-Conditioned Media in Combination with Oral Anti-Androgenic Drugs on Male Pattern Baldness: An Animal Study.Cell journal · 2023Article
- Current status of the applications of conditioned media derived from mesenchymal stem cells for regenerative medicine.Physiological research · 2023Review
- Cell Therapy for Androgenetic Alopecia: Elixir or Trick?Stem cell reviews and reports · 2023Review
- Stem cell secretome as a mechanism for restoring hair loss due to stress, particularly alopecia areata: narrative review.Journal of biomedical science · 2022Review
- Advancing Regenerative Cellular Therapies in Non-Scarring Alopecia.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional therapeutic applications of mesenchymal stromal cells (MSCs) focus on cell replacement and differentiation; however, increasing evidence suggests that most of their therapeutic effects are carried out by their various secretions. This study investigated the application of conditioned medium (CM) from human umbilical cord blood-derived MSCs (hUCB-MSCs) to improve hair growth and developed a method to reliably produce this optimized CM. Primed MSC-derived CM (P-CM) with combinations of TGF-β1 and LiCl was optimized by comparing its effects on the cell viability of dermal papilla cells (DPCs). P-CM significantly increased the viability of DPCs compared to CM. The secretion of vascular endothelial growth factor (VEGF) in DPCs was regulated by the macrophage migration inhibitory factor (MIF) in the P-CM secreted by MSCs. These findings suggest that P-CM can improve the efficacy in hair growth via a paracrine mechanism and that MIF in P-CM exerts hair growth-promoting effects via a VEGF-related β-catenin and p-GSK-3β [SER9] signaling pathway. Furthermore, clinical trials have shown that 5% P-CM improved androgenetic alopecia through producing an increased hair density, thickness, and growth rate, suggesting that this topical agent may be a novel and effective treatment option for patients with androgenetic alopecia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.